Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background

BMC Gastroenterology

Table 1 Summary of tumor incidence in cMyc + shp53 mice treated with vehicle (MP) vs. cMyc + shp53 mice treated with CCl₄ (MPC) from the survival study. Livers were harvested from MPC mice following death and from MP mice at the end of the experiment

	Total # of mice^a	% of mice with liver tumors	Average # of tumors per mouse	Total # of mice^b	% of mice with liver tumors	Average # of tumors per mouse
MP	21	38 % (8/21)^*	0.6^†	21	38 % (8/21)^‡	0.6^§
MPC	31	77 % (24/31)^*	9^†	24	100 % (24/24)^‡	11.7^§

^aEntire cohort
^bMice that died initially due to CCl₄-induced toxicity were excluded (i.e., those died before 50 days post hydrodynamic transfection)
^* P < 0.01, Fisher’s exact test. ^† P < 0.0001, Student’s t-test
^‡ P < 0.0001, Fisher’s exact test. ^§ P < 0.0001, Student’s t-test

ISSN: 1471-230X